Trials / Completed
CompletedNCT02040207
AM-101 in the Treatment of Post-Acute Tinnitus 2
AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) - an Open-Label Extension to the TACTT3 Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 487 (actual)
- Sponsor
- Auris Medical AG · Industry
- Sex
- All
- Age
- 18 Years – 76 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to test the safety and local tolerance of repeated treatment with AM-101.
Detailed description
This open-label extension study is assessing the safety and local tolerance of repeated treatment with AM-101 in subjects previously treated in the scope of the TACTT3 study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AM-101 | AM-101 gel for intratympanic injection |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2014-01-20
- Last updated
- 2023-09-14
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02040207. Inclusion in this directory is not an endorsement.